# US Acute Intermittent Porphyria Market

> US Acute Intermittent Porphyria Market Research Report: By Diagnosis (urine test, blood test, serum test, dna test, others), By Treatment (prophylactic hematin infusions, gonadotropin-releasing hormone analogues, others) and By End User (hospitals & clinics, medical research centers, others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.9%
- **2024:** $ 806.75 Million
- **2025:** $ 862.42 Million
- **2035:** $ 1,680 Million
- **Key Players:** Alnylam Pharmaceuticals (US), Pfizer (US), Bristol-Myers Squibb (US), Horizon Therapeutics (IE), Sarepta Therapeutics (US), Amgen (US), Vertex Pharmaceuticals (US), Novartis (CH)

**Report ID:** MRFR/Pharma/18312-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-acute-intermittent-porphyria-market-19859

---

## Market Summary

## **US Acute Intermittent Porphyria Market Overview**

### **Key US Acute Intermittent Porphyria Market Trends Highlighted**

The US Acute Intermittent Porphyria (AIP) market is experiencing significant trends driven by increasing awareness and better diagnosis of rare diseases. Healthcare providers and patients are more informed about AIP, leading to improved detection rates and management strategies, which positions the market for growth.

Moreover, the rising emphasis on personalized medicine and advancements in genetic testing are critical market drivers. These innovations enable tailored treatment plans for patients, enhancing their quality of life and treatment compliance. The US healthcare infrastructure supports this trend by facilitating research and clinical trials, which leads to the development of new therapies.

Opportunities are emerging in the realm of patient support programs and educational initiatives focused on AIP. These programs can help bridge the gap in understanding and managing the condition, which is often misunderstood and misdiagnosed. The demand for specialized healthcare services and support networks for AIP patients presents a robust opportunity for growth in this market.

In recent times, collaborations between pharmaceutical companies and research entities have become more common, aimed at accelerating drug development processes for AIP. Companies are focusing on innovative treatment options and approaches, including gene therapy and targeted medications that aim to address the root causes of the condition.

Additionally, the increasing availability of treatment options through specialty pharmacies and healthcare providers enhances access for patients in the US. This trend reflects a commitment to improving patient outcomes while addressing the challenges associated with a rare disease like acute intermittent porphyria.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Acute Intermittent Porphyria Market Drivers**

### **Rising Awareness and Diagnosis of Acute Intermittent Porphyria**

In the US, the increasing awareness and understanding of Acute Intermittent Porphyria (AIP) among healthcare professionals and patients is a significant driver for the US [Acute Intermittent Porphyria Market](../../../reports/acute-intermittent-porphyria-market-4713) Industry. With organizations like the American Porphyria Foundation driving educational initiatives, there has been a marked increase in diagnoses.

According to the Centers for Disease Control and Prevention (CDC), accurate diagnoses of rare diseases, including porphyria types, have increased by 20% over the past decade due to improved guidelines and professional training. This heightened awareness translates to more patients seeking treatment and support, ultimately fueling market growth.

### **Advancements in Treatment Options**

The US Acute Intermittent Porphyria Market Industry is poised for growth driven by advancements in treatment options available for patients. New treatments, such as the approval of specialized medications and therapies aimed at mitigating acute attacks and reducing symptoms, expand the arsenal of tools available for healthcare providers.

According to the Food and Drug Administration (FDA), there has been a surge in therapeutic approvals for rare diseases, with a recent report highlighting a 30% increase in novel drug approvals over the last three years. These developments are crucial in meeting the needs of patients suffering from AIP and can significantly contribute to a broader understanding and management of the disease.

### **Supportive Healthcare Policies and Funding**

Supportive healthcare policies and funding for rare diseases play a pivotal role in the growth of the US Acute Intermittent Porphyria Market Industry. The National Institutes of Health (NIH) has ramped up funding for research related to porphyrias, with a 15% increase noted from 2020 to 2022.

This financial backing enhances Research and Development (R&D) initiatives aimed at exploring innovative treatments and improving patient outcomes. Such policies not only stimulate research but also create an environment conducive to new product development, thereby increasing the availability of effective therapeutic options for AIP patients.

### **Growing Patient Advocacy and Community Support**

The rise of patient advocacy groups and community support systems is another key driver for the US Acute Intermittent Porphyria Market Industry. Organizations such as the Acute Porphyrias Association are actively engaged in raising awareness, providing resources, and advocating for legislative change on behalf of patients.

According to studies published by the National Organization for Rare Disorders, community support initiatives can enhance patient engagement by 25%, leading to improved treatment adherence and health outcomes. This community-driven approach fosters a better understanding of the disease and encourages more individuals to seek treatment, significantly contributing to market growth.

## **US Acute Intermittent Porphyria Market Segment Insights**

### **Acute Intermittent Porphyria Market Diagnosis Insights**

The Diagnosis segment of the US Acute Intermittent Porphyria Market plays a crucial role in the recognition and management of this rare metabolic disorder. Diagnosis primarily involves a variety of tests including urine tests, blood tests, serum tests, and DNA tests, among others, each serving its unique purpose in accurately identifying the condition.

The focus on these diagnostic methods is driven by the need for prompt and accurate identification of acute intermittent porphyria to avoid complications and to tailor suitable treatment strategies. The complexity of the disorder necessitates a multifaceted approach to diagnosis, amalgamating results from various tests to form a complete clinical picture. Moreover, advancements in diagnostic technologies and increased awareness among healthcare professionals contribute to enhancing the speed and accuracy of these diagnoses.

This segment's dynamics are influenced by factors such as rising incidence rates, improvements in technology, and increasing investment in diagnostic capabilities, which collectively boost its relevance in the overall landscape of the US Acute Intermittent Porphyria Market. With the ongoing research and development initiatives, the emphasis on sophisticated diagnostic tools continues to provide better patient outcomes and management strategies, thus solidifying the importance of the Diagnosis segment in the broader context of this specialized healthcare field.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Acute Intermittent Porphyria Market Treatment Insights**

The Treatment segment within the US Acute Intermittent Porphyria Market is characterized by several key approaches aimed at managing and mitigating the impact of this rare metabolic disorder. Among these, prophylactic hematin infusions are recognized for their crucial role in preventing acute attacks, making them a significant choice for patients with recurrent episodes.

This segment is underscored by the need for effective therapies, as the prevalence of Acute Intermittent Porphyria requires tailored treatment strategies for optimal patient management. The US market shows a growing emphasis on innovative approaches in treatment methodologies, driven by increasing awareness and ongoing Research and Development efforts. These dynamics point to a landscape filled with potential growth opportunities, as advancements in biochemical understanding and treatment efficacy become central to addressing the medical needs of patients suffering from this condition, ultimately leading to improved patient outcomes in the US healthcare setting.

### **Acute Intermittent Porphyria Market End User Insights**

The End User segment of the US Acute Intermittent Porphyria Market plays a crucial role in the overall landscape, comprising various categories that significantly influence market dynamics. Hospitals and clinics represent a pivotal part of this segment as they provide essential care and treatment for patients suffering from Acute Intermittent Porphyria, thus driving demand for specialized medical services and therapies.

These centers not only contribute to significant breakthroughs but also foster collaborations in Research and Development initiatives. This segment overall is characterized by increasing awareness of Acute Intermittent Porphyria, leading to enhanced diagnosis and proactive treatment approaches. The growing prevalence of the disorder further emphasizes the importance of these facilities in managing patient care effectively, ensuring that patients receive prompt and adequate treatment, which also reflects positively on the broader US healthcare system's capability to address rare diseases. The interplay between these End Users ultimately shapes the market's trajectory through improved capabilities and advancements in patient care.

## **US Acute Intermittent Porphyria Market Key Players and Competitive Insights**

The US Acute Intermittent Porphyria Market demonstrates a landscape characterized by a range of competitive forces that shape the strategies of companies operating within this niche sector. Given the complexity and rarity of acute intermittent porphyria, companies must navigate scientific, regulatory, and market dynamics effectively to deliver effective therapies.

The competitive insights reveal the ongoing innovation in treatment options, the significance of patient advocacy, and the necessity for robust market strategies. Stakeholders in this market must remain aware of emerging trends, including the prioritization of personalized medicine and the integration of technology in both treatment and patient management.

Companies are driven by the dual challenges of addressing patient needs while simultaneously managing their commercial interests in a market that is relatively small yet critically important for those affected by the condition.

Novartis holds a significant position within the US Acute Intermittent Porphyria Market, fueled by its commitment to advancing patient care through innovative solutions. The company demonstrates considerable strengths, including a well-established portfolio of pharmaceuticals that may play a role in treating symptoms associated with acute intermittent porphyria.

Novartis benefits from a strong research and development framework, which facilitates the discovery of new therapeutic agents aimed at alleviating the burden of disease. The company's extensive distribution networks and established relationships with healthcare providers and organizations enhance its market presence, supporting patient access to potentially life-altering treatments. Furthermore, Novartis's continuous investment in clinical trials ensures its offerings remain aligned with the evolving needs of the healthcare landscape.

Regeneron Pharmaceuticals is another key player in the US Acute Intermittent Porphyria Market, with a focus on innovative therapies that address rare and complex conditions. The company is known for its robust pipeline of products, including therapies that may offer significant benefits for patients suffering from acute intermittent porphyria.

Regeneron has built a solid market presence bolstered by a commitment to research, with substantial investments in clinical development allowing for advancements in treatment options. The firm has undertaken strategic mergers and acquisitions to enhance its capabilities and expand its product lines, reflecting its proactive approach to growth in this specialty area. By fostering partnerships and collaborations with healthcare providers, Regeneron aims to ensure that its therapies are accessible to those in need, reinforcing its standing as a leading entity in the fight against rare diseases in the US.

### **Key Companies in the US Acute Intermittent Porphyria Market Include**

## **US Acute Intermittent Porphyria Market Industry Developments**

In recent months, the US Acute Intermittent Porphyria Market has seen significant developments, particularly concerning advancements in treatment options and the financial performance of key players. Companies like Alnylam Pharmaceuticals continue to be at the forefront with their RNA interference therapies, anticipated to enhance treatment for acute porphyria manifestations.

Collaborations among firms, such as Regeneron Pharmaceuticals and Vertex Pharmaceuticals, are fostering innovation in drug development. There have been reports of market valuations improving due to increasing awareness of Acute Intermittent Porphyria and associated conditions, reflecting a rise in patient diagnoses and the demand for effective therapies.

Additionally, the merger landscape remains active, with notable interests in acquisitions that may influence the market dynamics, although there have been no major transactions reported in the last quarter. Historically, investments and partnerships, especially those announced in mid-2022, shaped the research collaborations among major pharmaceutical firms like Novartis and Roche, highlighting their commitment to this niche therapeutic area.

The growth trajectory remains optimistic as regulatory approvals for new treatments are anticipated to address unmet medical needs in the US population.

## **US Acute Intermittent Porphyria Market Segmentation Insights**

### **Acute Intermittent Porphyria Market Diagnosis Outlook**

### **Acute Intermittent Porphyria Market Treatment Outlook**

### **Acute Intermittent Porphyria Market End User Outlook**

## Market Drivers

### Increased Healthcare Expenditure

Healthcare expenditure in the US is on the rise, which positively impacts the acute intermittent-porphyria market. With the increasing allocation of funds towards rare diseases, healthcare systems are more equipped to provide comprehensive care for patients suffering from acute intermittent porphyria. This trend is reflected in the growing number of specialized clinics and treatment centers dedicated to managing rare conditions. As healthcare providers enhance their capabilities, patients are likely to receive better access to diagnostic and therapeutic services, thereby driving market growth. Furthermore, the expansion of insurance coverage for rare disease treatments may also contribute to increased market penetration.

### Advancements in Genetic Testing Technologies

The acute intermittent-porphyria market is benefiting from advancements in genetic testing technologies, which facilitate early diagnosis and personalized treatment approaches. The availability of more accurate and cost-effective genetic tests allows for the identification of at-risk individuals, leading to timely interventions. As genetic testing becomes more integrated into routine healthcare practices, the acute intermittent-porphyria market may see an increase in diagnosed cases, thereby expanding the patient population. Moreover, the ability to tailor treatments based on genetic profiles could enhance therapeutic efficacy, further driving market growth.

### Growing Patient Advocacy and Support Networks

The acute intermittent-porphyria market is positively impacted by the emergence of patient advocacy and support networks. These organizations play a crucial role in raising awareness about the disorder, providing resources for patients and families, and advocating for research funding. Increased visibility of acute intermittent porphyria through these networks may lead to higher diagnosis rates and improved access to treatment options. Furthermore, as patient communities grow, they can influence healthcare policies and encourage pharmaceutical companies to invest in the development of new therapies, thereby fostering a more robust market environment.

### Innovative Research and Development Initiatives

The acute intermittent-porphyria market is significantly influenced by ongoing research and development initiatives aimed at discovering novel therapies. Pharmaceutical companies are investing heavily in clinical trials to explore new treatment modalities, including gene therapy and small molecule drugs. The US government has allocated substantial funding for research in rare diseases, which may bolster the development of targeted therapies for acute intermittent porphyria. As a result, the market could witness the introduction of innovative treatment options that address the underlying causes of the disorder, potentially improving patient quality of life and expanding the market landscape.

### Rising Incidence of Acute Intermittent Porphyria

The acute intermittent-porphyria market is experiencing growth due to the rising incidence of this rare genetic disorder. Recent estimates suggest that the prevalence of acute intermittent porphyria in the US is approximately 1 in 20,000 individuals. This increasing number of diagnosed cases is likely to drive demand for effective treatment options and management strategies. As healthcare providers become more aware of the condition, the identification of new patients is expected to rise, further expanding the acute intermittent-porphyria market. Additionally, the growing understanding of the genetic basis of the disorder may lead to improved diagnostic tools, which could enhance patient outcomes and increase market potential.

## Future Outlook

The [Acute Intermittent Porphyria Market](https://www.marketresearchfuture.com/reports/acute-intermittent-porphyria-market-4713) is projected to grow at a 6.9% CAGR from 2025 to 2035, driven by advancements in diagnostics, treatment options, and increased awareness.

**New opportunities:**

- Development of targeted gene therapies for acute intermittent-porphyria patients. Expansion of telehealth services for remote patient monitoring and consultations. Investment in educational programs to raise awareness among healthcare professionals.

By 2035, the market is expected to achieve substantial growth, driven by innovative therapies and enhanced patient care.

## Segment Insights

### By Diagnosis: Urine Test (Largest) vs. DNA Test (Fastest-Growing)

The US acute intermittent-porphyria market exhibits a diverse range of diagnostic methods, with urine tests dominating the segment due to their established efficacy and reliability. This segment captures a significant portion of the market share as they are considered the gold standard for initial diagnosis. Meanwhile, blood tests and serum tests also hold considerable shares, reflecting their importance in diagnostic protocols. DNA tests, although currently smaller in market share, are gaining traction as genetic understanding of porphyria advances and personalized medicine becomes more prevalent.

Growth trends in this segment show a notable shift towards genetic testing options, with DNA tests emerging as a critical area of expansion. This change is largely driven by the increasing awareness of genetic factors associated with acute intermittent porphyria and the advancements in biotechnology. Additionally, the growing emphasis on early detection and tailored treatment plans is propelling the demand for DNA tests, marking them as a fast-growing component in the diagnostic landscape.

Urine Test (Dominant) vs. DNA Test (Emerging)

Urine tests have long been the dominant method for diagnosing acute intermittent porphyria, primarily due to their effectiveness in detecting porphyrins and their metabolites. This method is widely adopted across healthcare settings and is favored by clinicians for its simplicity and reliability. On the other hand, DNA tests are emerging as an innovative alternative that offers the potential for a more definitive diagnosis through genetic analysis. With advances in technology, these tests are becoming more accessible and are expected to play a crucial role in future diagnosis, aiding in the identification of hereditary factors and informing treatment strategies, thus presenting a dynamic shift in the overall diagnostic market.

### By Treatment: Prophylactic Hematin Infusions (Largest) vs. Gonadotropin-Releasing Hormone Analogues (Fastest-Growing)

In the US acute intermittent-porphyria market, Prophylactic Hematin Infusions currently dominate the treatment segment due to their established efficacy and frequent usage among patients. This segment accounts for a substantial share of the overall market, driven by the ongoing need to manage acute attacks effectively. Conversely, Gonadotropin-Releasing Hormone Analogues, while less established, are gaining traction and steadily increasing their market presence, attracting interest from both healthcare providers and patients seeking alternative therapies.

Growth trends within the treatment segment reveal a robust shift towards innovative therapeutic options. The push for more personalized medicine and targeted therapies is enhancing the adoption rates of Gonadotropin-Releasing Hormone Analogues as they display potential in providing preventative benefits. Additionally, increasing awareness about acute intermittent porphyria and rising patient adherence to treatment plans further contribute to the progress of both segments, albeit at different paces.

Prophylactic Hematin Infusions (Dominant) vs. Gonadotropin-Releasing Hormone Analogues (Emerging)

Prophylactic Hematin Infusions are characterized by their long-standing role in managing acute intermittent porphyria, effectively mitigating crises and ensuring patient safety. This treatment is recognized for its safety profile and is often the first choice among physicians. On the other hand, Gonadotropin-Releasing Hormone Analogues represent a novel approach, aimed at hormone regulation and exhibiting potential for preventative measures. As awareness and clinical research surrounding acute intermittent porphyria expands, the latter's emerging status could lead to increased prescriptions and market influence, coupled with ongoing improvements in treatment efficacy.

### By End-user: Hospitals & Clinics (Largest) vs. Medical Research Centers (Fastest-Growing)

In the US acute intermittent-porphyria market, the distribution of market share among end-users reveals that hospitals and clinics currently hold the largest portion. This segment is well-established due to its crucial role in diagnosis, treatment, and management of acute intermittent porphyria cases, providing comprehensive care to patients. Following closely is the medical research centers segment, which while smaller in market share, plays a vital role in innovation and advancing treatment options through cutting-edge research.

Growth trends indicate that the hospitals and clinics segment is expected to maintain its dominant position, driven by increasing patient volumes and advancements in diagnostic technologies. On the other hand, medical research centers are projected to experience significant growth as they contribute to the development of new therapies and clinical trials, addressing the unmet needs in the treatment of acute intermittent porphyria. The demand for collaborative research initiatives is also expected to bolster this segment's expansion.

Hospitals & Clinics (Dominant) vs. Medical Research Centers (Emerging)

The hospitals and clinics segment stands as the dominant player in the US acute intermittent-porphyria market due to its extensive infrastructure and established protocols for patient care. These facilities are equipped with the necessary resources to handle acute cases effectively, ensuring timely diagnosis and management. Additionally, they contribute significantly to treatment adherence and patient education. Conversely, the medical research centers segment is emerging rapidly as a critical force in shaping future treatment landscapes. These centers focus on innovative research and the development of new therapies, actively conducting clinical trials to explore groundbreaking treatment methodologies. Their collaboration with pharmaceutical companies and academic institutions further enhances their potential for growth, as they seek to address the challenges associated with acute intermittent porphyria.

## Competitive Benchmarking

The acute intermittent-porphyria market is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key players such as Alnylam Pharmaceuticals (US), Pfizer (US), and Horizon Therapeutics (IE) are at the forefront, leveraging their research capabilities to develop novel therapies. Alnylam Pharmaceuticals (US) focuses on RNA interference technology, which appears to provide a unique approach to treating genetic disorders, including acute intermittent porphyria. Meanwhile, Pfizer (US) has been enhancing its portfolio through strategic acquisitions, aiming to bolster its presence in rare disease markets. Horizon Therapeutics (IE) emphasizes patient-centric approaches, which may enhance its competitive edge by fostering loyalty and trust among healthcare providers and patients alike.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies is palpable. Their collective strategies not only drive innovation but also create a competitive environment where agility and responsiveness to market needs are paramount.
In October Alnylam Pharmaceuticals (US) announced a collaboration with a leading biotechnology firm to enhance its research capabilities in gene therapies. This partnership is likely to accelerate the development of innovative treatments for acute intermittent porphyria, potentially positioning Alnylam as a leader in this niche market. The strategic importance of this collaboration lies in its potential to expand Alnylam's therapeutic offerings and improve patient outcomes through advanced treatment modalities.
In September Pfizer (US) launched a new initiative aimed at streamlining its clinical trial processes for rare diseases, including acute intermittent porphyria. This initiative is expected to reduce the time to market for new therapies, thereby enhancing Pfizer's competitive positioning. The strategic significance of this move is underscored by the growing demand for rapid and effective treatment solutions in the rare disease sector, which could lead to increased market share for Pfizer.
In August Horizon Therapeutics (IE) expanded its patient support programs, focusing on enhancing access to treatments for acute intermittent porphyria. This initiative is indicative of Horizon's commitment to patient engagement and may serve to strengthen its brand loyalty. The strategic importance of this expansion lies in its potential to improve treatment adherence and patient satisfaction, which are critical factors in the competitive landscape.
As of November current trends in the acute intermittent-porphyria market are increasingly defined by digitalization and the integration of artificial intelligence in drug development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve, shifting from price-based competition to a focus on technological advancements and supply chain reliability. This transition may ultimately enhance the overall quality of care for patients suffering from acute intermittent porphyria.

## Recent News & Developments

In recent months, the US Acute Intermittent Porphyria Market has seen significant developments, particularly concerning advancements in treatment options and the financial performance of key players. Companies like Alnylam Pharmaceuticals continue to be at the forefront with their RNA interference therapies, anticipated to enhance treatment for acute porphyria manifestations.

Collaborations among firms, such as Regeneron Pharmaceuticals and Vertex Pharmaceuticals, are fostering innovation in drug development. There have been reports of market valuations improving due to increasing awareness of Acute Intermittent Porphyria and associated conditions, reflecting a rise in patient diagnoses and the demand for effective therapies.

Additionally, the merger landscape remains active, with notable interests in acquisitions that may influence the market dynamics, although there have been no major transactions reported in the last quarter. Historically, investments and partnerships, especially those announced in mid-2022, shaped the research collaborations among major pharmaceutical firms like Novartis and Roche, highlighting their commitment to this niche therapeutic area.

The growth trajectory remains optimistic as regulatory approvals for new treatments are anticipated to address unmet medical needs in the US population.

## Report Scope

| MARKET SIZE 2024 | 806.75(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 862.42(USD Million) |
| MARKET SIZE 2035 | 1680.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.9% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Alnylam Pharmaceuticals (US), Pfizer (US), Bristol-Myers Squibb (US), Horizon Therapeutics (IE), Sarepta Therapeutics (US), Amgen (US), Vertex Pharmaceuticals (US), Novartis (CH) |
| Segments Covered | Diagnosis, Treatment, End-user |
| Key Market Opportunities | Advancements in gene therapy may enhance treatment options in the acute intermittent-porphyria market. |
| Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the acute intermittent-porphyria market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation for the US acute intermittent-porphyria market in 2024?**
A: The overall market valuation for the US acute intermittent-porphyria market was $806.75 Million in 2024.

**Q: What is the projected market valuation for the US acute intermittent-porphyria market by 2035?**
A: The projected market valuation for the US acute intermittent-porphyria market is $1680.0 Million by 2035.

**Q: What is the expected CAGR for the US acute intermittent-porphyria market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US acute intermittent-porphyria market during the forecast period 2025 - 2035 is 6.9%.

**Q: Which companies are considered key players in the US acute intermittent-porphyria market?**
A: Key players in the US acute intermittent-porphyria market include Alnylam Pharmaceuticals, Pfizer, Bristol-Myers Squibb, Horizon Therapeutics, Sarepta Therapeutics, Amgen, Vertex Pharmaceuticals, and Novartis.

**Q: What were the revenue figures for urine tests in the US acute intermittent-porphyria market?**
A: The revenue figures for urine tests in the US acute intermittent-porphyria market ranged from $80.68 Million to $170.0 Million.

**Q: How much revenue is projected for prophylactic hematin infusions in the treatment segment?**
A: The revenue projected for prophylactic hematin infusions in the treatment segment is between $300.0 Million and $600.0 Million.

**Q: What is the revenue range for hospitals and clinics as end-users in the US acute intermittent-porphyria market?**
A: The revenue range for hospitals and clinics as end-users in the US acute intermittent-porphyria market is between $400.0 Million and $800.0 Million.

**Q: What are the projected revenues for blood tests in the US acute intermittent-porphyria market?**
A: The projected revenues for blood tests in the US acute intermittent-porphyria market range from $161.35 Million to $340.0 Million.

**Q: What is the revenue range for gonadotropin-releasing hormone analogues in the treatment segment?**
A: The revenue range for gonadotropin-releasing hormone analogues in the treatment segment is between $250.0 Million and $500.0 Million.

**Q: What were the revenue figures for medical research centers as end-users in the US acute intermittent-porphyria market?**
A: The revenue figures for medical research centers as end-users in the US acute intermittent-porphyria market ranged from $300.0 Million to $600.0 Million.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-acute-intermittent-porphyria-market-19859*